Literature DB >> 23834812

Poxvirus vectors.

Joost H C M Kreijtz, Sarah C Gilbert, Gerd Sutter.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23834812     DOI： 10.1016/j.vaccine.2013.06.073

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  10 in total

1.  The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo.

Authors:  Lorena F D de Freitas; Rafael P Oliveira; Mariana C G Miranda; Raíssa P Rocha; Edel F Barbosa-Stancioli; Ana Maria C Faria; Flávio G da Fonseca
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

Review 2.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Multivalent and Multipathogen Viral Vector Vaccines.

Authors:  Katharina B Lauer; Ray Borrow; Thomas J Blanchard
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

4.  Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome.

Authors:  Anahita Fathi; Christine Dahlke; Verena Krähling; Alexandra Kupke; Nisreen M A Okba; Matthijs P Raadsen; Jasmin Heidepriem; Marcel A Müller; Grigori Paris; Susan Lassen; Michael Klüver; Asisa Volz; Till Koch; My L Ly; Monika Friedrich; Robert Fux; Alina Tscherne; Georgia Kalodimou; Stefan Schmiedel; Victor M Corman; Thomas Hesterkamp; Christian Drosten; Felix F Loeffler; Bart L Haagmans; Gerd Sutter; Stephan Becker; Marylyn M Addo
Journal:  Nat Commun       Date:  2022-07-19       Impact factor: 17.694

5.  A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.

Authors:  Joost H C M Kreijtz; Lidewij C M Wiersma; Heidi L M De Gruyter; Stella E Vogelzang-van Trierum; Geert van Amerongen; Koert J Stittelaar; Ron A M Fouchier; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2014-09-22       Impact factor: 5.226

Review 6.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

7.  Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.

Authors:  Bahar Ramezanpour; Esther S Pronker; Joost H C M Kreijtz; Albert D M E Osterhaus; E Claassen
Journal:  Vaccine       Date:  2015-06-03       Impact factor: 3.641

Review 8.  Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.

Authors:  Virginia Aida; Vasilis C Pliasas; Peter J Neasham; J Fletcher North; Kirklin L McWhorter; Sheniqua R Glover; Constantinos S Kyriakis
Journal:  Front Vet Sci       Date:  2021-04-15

Review 9.  Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.

Authors:  Arwen F Altenburg; Joost H C M Kreijtz; Rory D de Vries; Fei Song; Robert Fux; Guus F Rimmelzwaan; Gerd Sutter; Asisa Volz
Journal:  Viruses       Date:  2014-07-17       Impact factor: 5.048

10.  Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.

Authors:  María Pía Holgado; Juliana Falivene; Cynthia Maeto; Micaela Amigo; María Fernanda Pascutti; María Belén Vecchione; Andrea Bruttomesso; Gabriela Calamante; María Paula Del Médico-Zajac; María Magdalena Gherardi
Journal:  Viruses       Date:  2016-05-23       Impact factor: 5.048
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.